ALSO NOTED: FDA studies blindness; Roche gets OK for HIV drug; FDA approves Zemplar; and much more...

> The FDA is examining a handful of cases in which men taking Viagra have gone blind. The agency says that there is currently no known link, but that it will investigate. Story

> Roche has received European marketing approval for 500 mg formulation of the HIV drug Invirase. Story

> The FDA has approved Abbott's Zemplar (paricalcitol) for the prevention and treatment of secondary hyperparathyroidism. Release

> The FDA has approved Novartis Pharmaceuticals' extended release form of Focalin for ADHD, which is licensed from Celgene. Story

> Ariad has begun its first clinical trial of oral AP23573 in patients with relapsed or refractory cancers. Release

> NovaDel Pharma of Flemington, New Jersey, raised $7 million in a private placement. Release

> Santarus has filed an NDA for Zegerid chewable tablets. Release

> King Pharmaceuticals and Astellas have filed suit against several generic drug makers following their ANDA for Adenoscan, a pharmacologic stress agent. Release

And Finally... A group of scientists is challenging new research claiming that people who are slightly overweight live longer. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.